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Background: Arterial calcification is an important pathological change of diabetic vascular complication. Osteoblastic
differentiation of vascular smooth muscle cells (VSMCs) plays an important cytopathologic role in arterial calcification.
The glucagon-like peptide-1 receptor agonists (GLP-1RA), a novel type of antidiabetic drugs, exert cardioprotective
effects through the GLP-1 receptor (GLP-1R). However, the question of whether or not GLP-1RA regulates osteoblastic
differentiation and calcification of VSMCs has not been answered, and the associated molecular mechanisms have not
been examined.
Methods: Calcifying VSMCs (CVSMCs) were isolated from cultured human arterial smooth muscle cells through limiting
dilution and cloning. The extent of matrix mineralization was measured by Alizarin Red S staining. Protein expression
and phosphorylation were detected by Western blot. Gene expression of receptor activator of nuclear factor-κB ligand
(RANKL) was silenced by small interference RNA (siRNA).
Results: Exenatide, an agonist of GLP-1 receptor, attenuated β-glycerol phosphate (β-GP) induced osteoblastic
differentiation and calcification of human CVSMCs in a dose- and time-dependent manner. RANKL siRNA
also inhibited osteoblastic differentiation and calcification. Exenatide decreased the expression of RANKL in a
dose-dependent manner. 1,25 vitD3 (an activator of RANKL) upregulated, whereas BAY11-7082 (an inhibitor of
NF-κB) downregulated RANKL, alkaline phosphatase (ALP), osteocalcin (OC), and core binding factor α1 (Runx2)
protein levels and reduced mineralization in human CVSMCs. Exenatide decreased p-NF-κB and increased p-AMPKα
levels in human CVSMCs 48 h after treatment. Significant decrease in p-NF-κB (p-Ser276, p-Ser536) level was observed
in cells treated with exenatide or exenatide + BAY11-7082.
Conclusion: GLP-1RA exenatide can inhibit human VSMCs calcification through NF-κB/RANKL signaling.
Keywords: Arterial calcification, Vascular smooth muscle cells, Osteoblastic differentiation, Glucagon-like
peptide-1, DiabetesIntroduction
Diabetes mellitus is a major risk factor for the develop-
ment of cardiovascular disease [1]. Currently, treatment of
diabetes and its cardiovascular complications with classic
drugs is effective in less than 50% of patients [2]. Novel
therapies are therefore required to manage diabetes melli-
tus and mitigate cardiovascular risks. GLP-1 is an incretin
hormone that is rapidly released from intestinal L-cells
after food intake. GLP-1 has insulinotropic effects, and it
lowers blood glucose in a glucose-dependent manner [3].
Targeting of glucagon-like peptide-1 receptor (GLP-1R)* Correspondence: Liuyoushuo@yeah.net
Department of Geriatrics, Institute of Aging and Geriatrics, The Second
Xiangya Hospital, Central South University, 139 Middle Renmin Road,
Changsha, Hunan 410011, P.R. China
© 2014 Zhan et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.has been developed to complement conventional treat-
ment options for diabetes mellitus. This class of drugs is
currently undergoing clinical trials for the treatment of
type 2 diabetes.
Exenatide is a synthetic peptide sharing 53% sequence
homology with GLP-1 and has been used as an agonist
of mammalian GLP-1 receptor (GLP-1RA) for the treat-
ment of type 2 diabetes [4,5]. In clinical trials, treatment
with exenatide once a week assisted more patients in
reaching the majority of ADA-recommended therapeutic
goals than treatments with other drugs, such as sitaglip-
tin, pioglitazone, or insulin glargine [6]. However, the
residual adverse effect of sulphonylurea was also higher
in patients who were treated with exenatide once a weektd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Zhan et al. Cardiovascular Diabetology 2014, 13:153 Page 2 of 10
http://www.cardiab.com/content/13/1/153[7]. Compared to conventional treatments, GLP-1RAs not
only have an advantage in lowering blood sugar, but also
have other benefits. For example, it has been reported
that exenatide confers cardioprotection [4,5,8]. Arterial
calcification is an important pathological change of
diabetic vascular complication, which results in cardio-
vascular events and amputations [9]. However, the
question of whether or not GLP-1RA regulates arterial
calcification has not been answered, and the associated
molecular mechanisms have not been examined.
Studies have suggested that arterial calcification is an
active and tightly regulated process similar to bone for-
mation [10,11]. The differentiation of vascular smooth
muscle cell (VSMC) to an osteoblastic phenotype is a key
component of the cytopathologic foundation of arterial
calcification [12-15]. Calcifying VSMCs (CVSMCs) can
spontaneously form calcification nodules and express
osteoblast phenotype genes, such as ALP, OC, and Runx2
[16,17], which are often used together as a cell model in
arterial calcification research [18]. Receptor activator of
nuclear factor-κB ligand (RANKL) is a member of the
tumor necrosis factor family and is important for bone
remodeling [19]. Researchers have discoved that OPG-
deficient mice develop severe osteoporosis and arterial
calcification [20,21]. OPG inhibits nuclear kappa B
(NF-κB) by binding RANKL. RANKL directly promotes
calcification of VSMCs [22]. In addition, elevated serum
OPG has been observed to be associated with vascular
calcification in humans with T2DM [23]. The elevated
serum OPG may interfere with RANK/RANKL interactions
in the vascular wall. In cardiovascular diseases, RANKL is
positively associated with circulating OPG [24].
In the present study, we investigated the effects of exe-
natide and RANKL in the osteoblastic differentiation
and calcification of CVSMCs and examined the associ-
ated mechanisms.
Materials and methods
Cell culture and in vitro calcification
Human VSMCs were isolated from excess donor vascula-
ture after kidney transplantations as previously described
[25]. Briefly, the arterial tissues were removed and rinsed
several times in Hanks’s balanced salt solution. The
arterial tissues were then minced and digested in 5 ml of
digestion solution (0.25 mg/ml soybean trypsin inhibitor,
0.125 mg/ml elastase, 2.0 mg/ml crystallized bovine albu-
min, 10 mg/ml collagenase I, and 15 mM HEPES) at 37°C
for 45 min. The digested cells were filtered through a
sterile 100-mM nylon mesh, centrifuged at 1,000 rpm for
10 min, and washed with Dulbecco’s modified Eagle’s
medium (DMEM) containing high glucose concentration
(4500 mg/L) and 10% FBS (Gibco-BRL). CVSMCs were
isolated from cultured VSMCs when multicellular nod-
ules spontaneously appeared. Briefly, cells were clonedby limiting dilution. Colonial cells were identified as
CVSMCs by positive α-actin staining and by high ALP
expression and formation of calcified nodules. This study
was approved by the Ethics Review Board of Second
Xiangya Hospital, Central South University. Written
informed consent was obtained from patients.
Mineralization assay
The extent of matrix mineralization in cultured CVSMCs
was determined by Alizarin Red S staining. Briefly, cells
were fixed with 4% formaldehyde for 10 min at room
temperature and exposed to 2% Alizarin Red S for 5 min.
Cells were then washed with PBS to remove excess dye.
For quantitative analysis of Alizarin Red S staining, the
dye was released from the cell matrix by incubating with
cetyl-pyridinium chloride for 15 min. The amount of
released dye was quantified by spectrophotometry at
540 nm. Results were normalized to the total amount
of cellular proteins.
Osteoblastic differentiation
Human CVSMCs were fixed in 4% paraformaldehyde,
washed with Tris–Tween-20 buffer, and permeabilized for
20 min in buffer containing 0.1% triton-X. After blocking
for 1 h, cells were incubated with primary antibodies over-
night at 4°C, followed by secondary antibodies for 30 min.
anti-ALP, anti-Runx2, and anti-OC primary antibodies
and secondary antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
To analyze the dose dependence of calcification on
exenatide, CVSMCs were cultured with β-GP (10 mM)
and 0, 100 pM, 1 nM, and 100 nM of exenatide in serum-
free high glucose DMEM for 48 hrs. ALP activity was
determined using the spectrophotometric measurement of
p-nitrophenol level in the culture medium [26]. Osteocal-
cin level was measured using a radioimmunoassay kit
(DiaSorin, Stillwater, MN, USA). The ALP activity and OC
level were then normalized to the total amount of cellular
protein.
Silencing of RANKL by RNA interference
Three RANKL target sequences (S1: 5’-GTGCAGAAAT
GGCGAGAATAC-3’, S2: 5’-GGAUGGCUCAUGGUUA
GAUTT-3’, S3: 5’-CGGAUCAGGAUGCAACAUATT-3’)
were used to design and synthesize siRNA. A scrambled
siRNA sequence was used as a control for siRNA trans-
fection as previously described [27]. CVSMCs were plated
onto 60-mm dishes and cultured in DMEM without
antibiotics 24 hours before siRNA transformation. Cells
were transfected with RANKL siRNA or control siRNA
using Lipofectamine 2000 (Invitrogen, Grand Island, NY)
according to the instructions of the manufacturer and
continually cultured for 72 hours. Cells were then har-
vested for analyses of RANKL expression. Among the 3
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the most effective in silencing RANKL expression and was
used for further experiments in this study.
Western blot
Protein concentration was measured using a BCA Protein
Assay kit (Beyotime, Shanghai, China). 20-μg of total pro-
tein was loaded onto a 12% SDS-PAGE gel and transferred
onto nitrocellulose membranes. After blocking with 5%
non-fat milk for 1 h, membranes were incubated with
primary antibody overnight at 4°C and subsequently
incubated with HRP-labeled secondary antibody (1:2000
dilution) for 2 h at room temperature. Reactive proteins
were detected using chemiluminescent reagents (Pierce,
Rockford, IL, USA). To control for loading efficiency,
the blots were stripped and reprobed with GAPDH
(glyceraldehyde-3-phosphatedehydrogenase) antibody. Pri-
mary antibodies for RANKL, AMPKα, Phospho-AMPKα
Thr172, ERK1/2, Phospho-ERK, JNK, Phospho-JNK, NF-κB
p65, phospho-NF-κB (p-NF-κB Ser276, p-NF-κB Ser529 and
p-NF-κB Ser536), and GAPDH were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Statistical analysis
Data were presented as mean ± standard deviation (SD)
and analyzed using Statistical Product and Service Solu-
tions (SPSS, version 17.0). Differences between two groups
were analyzed using Student’s t-test. P <0.05 was consid-
ered statistically significant.
Results
Effects of exenatide and RANKL-siRNA on osteoblastic
differentiation and calcification of human CVSMCs
To determine the effect of GLP-1RA and RANKL on the
osteoblastic differentiation and calcification of human
CVSMCs, a GLP-1 receptor agonist (exenatide) and
RANKL siRNA were used. Figure 1A shows that RNA
interference efficiently knocked down RANKL gene
expression in human CVSMCs. Treatment with siRNA-
RANKL blocked the expression of RANKL protein in
human CVSMCs. Further examination found that exena-
tide inhibited ALP activity (Figure 1B) and OC secretion
(Figure 1C) in β-GP-treated VSMCs in a dose-dependent
manner. Two nM of exenatide was selected for further
studies. Two nM of exenatide downregulated ALP protein
level in human CVSMCs compared to cells without exe-
natide treatment (Figure 1D and E). Moreover, treatment
of human CVSMCs with exenatide + RANKL-siRNA or
RANKL-siRNA alone downregulated ALP and RANKL
protein levels (Figure 1D and E). Alizarin Red S staining
showed weaker staining in CVSMCs treated with exena-
tide + RANKL-siRNA compared to control cells or cells
treated with exenatide or RANKL-siRNA alone (Figure 1
F and G). These results indicated that exenatide treatmentand RANKL siRNA attenuated the osteoblastic differenti-
ation and calcification of human CVSMCs.
Dose-effect relationship of the regulation of RANKL
expression by exenatide in human CVSMCs and possible
signaling pathways
Recent studies have demonstrated that several signaling
pathways regulate RANKL expression in osteoblasts or
VSMCs, such as AMPK, JNK, ERK1/2 and NF-κB sig-
naling [11,28,29]. As shown in Figure 2A, exenatide
decreased the expression of RANKL in a dose-dependent
manner. Also, exenatide decreased p-NF-κB and increased
p-AMPKα levels in human CVSMCs 48 h after treatment.
In contrast, exenatide did not affect the protein level of
AMPKα, ERK1/2, p-ERK1/2, JNK, p-JNK, or NF-κB
(Figure 2).
Effects of NF-κB inhibitor and RANKL activator on
exenatide-inhibited osteoblastic differentiation and
calcification of human CVSMCs
Human CVSMCs were treated with or without exenatide
(2 nM), BAY11-7082 (an inhibitor of NF-κB, 10 μM), and
1,25-dihydroxyvitamin D3 (1,25vitD3) (an activator of
RANKL, 10-7 M) [30] for 48 h. The expression of ALP,
OC, and Runx2 proteins was detected by Western blot.
Results showed that 2 nM of exenatide downregulated
ALP, OC, and Runx2 protein levels in human CVSMCs
compared to cells without exenatide treatment (Figure 3A
and 3B). 1,25vitD3 upregulated ALP, OC, and Runx2
protein levels in human CVSMCs compared to cells treated
with exenatide alone. Treatment of human CVSMCs with
2 nM of exenatide and 10 μM of BAY11-7082 more effect-
ively downregulated ALP, OC, and Runx2 protein levels
compared to cells treated with 2 nM of exenatide, 1,25
vitD3, or cells without treatment. Weaker Alizarin Red S
staining was observed in CVSMCs cultured with exenatide
alone than in cells cultured without exenatide. Stronger
Alizarin Red S staining was observed in human CVSMCs
cultured with exenatide and 1,25 vitD3 than in cells cul-
tured with exenatide alone or exenatide + BAY11-7082
(Figure 3C and D). These results suggested that exenatide
treatment may attenuate osteoblastic differentiation and
calcification of human CVSMCs through NF-κB signaling.
RANKL activation exhibits the opposite effect.
Roles of RANKL and phosphorylation of NF-κB in
exenatide-inhibited osteoblastic differentiation and
calcification of human CVSMCs
We further investigated RANKL, NF-κB and p-NF-κB
(p-Ser529, p-Ser276, p-Ser536) protein levels in human
CVSMCs treated with or without exenatide (2 nM),
BAY11-7082 (10 μM), and 1,25 vitD3 (10-7 M) (Figure 4A).
The protein level of RANKL was significantly decreased
in cells treated with exenatide alone compared to cells
Figure 1 (See legend on next page.)
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Figure 2 Exenatide–inhibited osteoblastic differentiation and calcification of human CVSMCs requires NF-κB. A) Human CVSMCs were
treated with different concentrations of exenatide for 48 hrs. Representative Western blot of RANKL, AMPKα, p-AMPKα, ERK1/2, p- ERK1/2, JNK,
p-JNK, NF-κB, p-NF-κB protein expression. B) Semi-quantitative analysis of bands in Western blot. GAPDH was used as the loading control. Bars
represent mean ± SD. *P < 0.01 and #P < 0.001 between two indicated groups. N = 5.
(See figure on previous page.)
Figure 1 Exenatide and RANKL-siRNA attenuate osteoblastic differentiation and calcification of human CVSMCs. A) Representative
Western blot of RANKL protein levels in human CVSMCs transfected with control siRNA (C-siRNA) or R-siRNA for 48 hours. B) Exenatide inhibited
ALP activities in β-GP-treated VSMCs in a dose-dependent manner. VSMCs were treated for 48 hrs. N = 5, **P <0.001 vs. control (0 concentration
of exenatide). C) Exenatide inhibited OC levels in β-GP-treated VSMCs in a dose-dependent manner. VSMCs were treated for 48 hrs. N = 5, **P <0.001
vs. 0 concentration of exenatide. D) Representative Western blot of ALP and RANKL protein expressions. Human CVSMCs were treated with or
without exenatide (2 nM) and RANKL-siRNA (R-siRNA) for 48 h. GAPDH was used as the loading control. E) Semi-quantitative analysis of bands in
Western blot at 48 hrs in each group. Bars represent mean ± SD. #P < 0.001 between two indicated groups. N = 5. F) Representative Alizarin Red S
staining. Human CVSMCs were treated with various agents for 15 days. Magnification × 200. G) Quantification of Alizarin red S staining. The dye was
extracted and quantified as described in the Method section. Bars represent mean ± SD. #P < 0.001 between two indicated groups. N = 5.
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Figure 3 (See legend on next page.)
Zhan et al. Cardiovascular Diabetology 2014, 13:153 Page 6 of 10
http://www.cardiab.com/content/13/1/153
(See figure on previous page.)
Figure 3 Exenatide–inhibited osteoblastic differentiation and calcification of human CVSMCs can be regulated by NF-κB inhibitor and
RANKL activator. A, B) Human CVSMCs were treated with exenatide (2 nM), 1,25 VitD3 (10-7 M), and BAY11-7082 (10 μM) for 48 h. ALP, OC and
Runx2 protein expressions were detected by Western blot. GAPDH was used as the loading control Bars represent mean ± SD. #P < 0.001 between
two indicated groups. N = 5. C) Human CVSMCs were treated with various agents for 15 days. The calcification was visualized by Alizarin Red S
staining. Magnification × 200. D) Quantification of Alizarin red S staining. The dye was extracted and quantified as described in the Method
section. Bars represent mean ± SD. #P < 0.001 between two indicated groups. N = 5.
Figure 4 The effect of exenatide in the phosphorylation of NF-κB and the expression of RANKL in human CVSMCs. A) Human CVSMCs
were treated with exenatide (2 nM),1,25VitD3(10-7 M) and BAY11-7082(10 μM) for 48 h. RANKL, NF-κB, p-NF-κB (S529, S276, S536) levels were
detected by Western blot. GAPDH was used as the loading control. B) These results were reported at 48 h in each group. Bars represent
mean ± SD. *P < 0.01 and #P < 0.001 between two indicated groups. N = 5.
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the NF-κB inhibitor BAY11-7082 downregulated the
protein level of RANKL. Conversely, pretreatment of
cells with the RANKL activator 1,25 vitD3 upregulated
the protein level of RANKL. These results indicated
that RANKL is a downstream mediator for exenatide–
reduced osteoblastic differentiation and calcification of
CVSMCs. Western blot showed a significant decrease
in p-NF-κB (p-Ser276, p-Ser536) level in cells treated with
exenatide or exenatide + BAY11-7082 compared to cells in
the no treatment group (Figure 4A and 4B). No changes
in total NF-κB or NF-κB p65 (p-Ser529) levels were
observed in human CVSMCs with different treatments.
These results indicated that suppression of NF-κB phos-
phorylation, but not its expression, is necessary for
exenatide-inhibited osteoblastic differentiation and cal-
cification in human CVSMCs.
Discussion
Type 2 diabetes mellitus is a progressive disease charac-
terized by persistent insulin resistance and declining
pancreatic β-cell function [31]. However, long-term gly-
cemic control is hard to achieve because of deteriorating
β-cell function. A multicentre randomized parallel-group
trial suggested that exenatide was more effective in
improving β-cell function compared to insulin and piogl-
tazone; hence, early initiation of β-cell-protective therapy
with exenatide may halt the decline in β-cell function
in type 2 diabetes [32]. Indeed, two years after treat-
ment initiation, patients on exenatide twice a day showed
a significant reduction in body mass index and hemog-
lobin A1c compared with patients treated with a long-
acting insulin analog [33]. In addition, even after only
three months, exenatide therapy exhibited similar effects
on microvascular endothelial function, inflammation
markers, oxidative stress, and vascular activation as
metformin in patients with obesity and pre-diabetes
[34]. In this study, exenatide was able to inhibit human
VSMCs calcification in cells cultured with high glucose
concentration, suggesting that exenatide may exert its
effect dependent on glucose concentration. Therefore,
the detected alterations may play a role in the prevention
of diabetes-induced vascular calcification.
Recent studies have suggested that GLP-1RA exhibits
potential cardioprotective properties in addition to its
role in lowering glucose level [35]. In animal models,
exenatide has been demonstrated to be capable of pro-
tecting the heart against ischemia/reperfusion injury
[4,36], reducing infarct size, improving cardiac function
[4], and retarding atherosclerotic lesion formation [37].
Bao et al study demonstrated that sustained GLP-1 recep-
tor activation plays an important role in providing cardio-
protection in the setting of acute myocardial I/R injury
[38]. However, the question of whether or not GLP-1RAprotects the cardiovascular system by regulating VSMCs
osteoblastic differentiation and calcification has not been
answered, and the associated molecular mechanism is still
unclear. Expression of ALP, OC, and Runx2 is a marker of
osteoblastic differentiation, while matrix mineralization is
a hallmark of the osteoblast phenotype [14,15]. In this
study, we demonstrated that exenatide downregulated the
expression of ALP, OC, and Runx2. In addition, exenatide
inhibited mineralized nodule formation. We show for
the first time that the GLP-1RA exenatide can inhibit
osteoblastic differentiation and calcification of human
CVSMCs.
Overexpression of RANKL has been found to stimu-
late VSMC mineralization [19-22,39]. However, most of
the evidence for the direct role of RANKL signaling in
arterial calcification is derived from animal studies. Little
data is available on the role of RANKL signaling in rela-
tion to arterial calcification in human cells. The present
study showed that exenatide inhibited RANKL expression
in human CVSMCs through the NF-κB pathway and miti-
gated CVSMCs calcification. These findings suggest that
exenatide inhibits the calcification of human CVSMCs via
the NF-κB/RANKL signaling pathway.
The RANKL complex, consisting of the membrane-
bound RANK, its ligand RANKL, and the decoy receptor
OPG, is thought to be important for bone metabolism.
Osteoblasts express OPG and RANKL, which regulate
osteoclast differentiation through the activation of RANK
[40]. The present study showed that exenatide could
decrease the expression of RANKL and inhibit the ex-
pression of ALP, OC, and Runx2 in human CVSMCs.
Furthermore, inhibition of RANKL expression by siRNA
abrogated the role of exenatide in ALP expression in
human CVSMCs. These findings suggest that RANKL is a
key mediator in exenatide-induced inhibition of osteo-
blastic differentiation of human CVSMCs.
The NF-κB, MAPK, ERK, and NFAT signaling pathways
have been demonstrated to regulate RANKL expression in
osteoblast cells [29,41] and VSMCs [11,28]. In this study,
exenatide inhibited the activation of NF-κB in human
CVSMCs. Pretreatment of cells with NF-κB inhibitor
inhibited the expression of RANKL in human CVSMCs.
The NF-κB inhibitor BAY11-7082 abolished the effect
of RANKL activator (1,25 vitD3) - promoted RANKL
expression. In contrast, no changes in AMPKα, ERK1/
2, p-ERK1/2, JNK, and p-JNK protein level have been
observed in this study.
The NF-κB family consists of five members, RelA
(p65), RelB, NF-κB1 (p50), NF-κB2 (p52), and c-Rel. p65
heterodimer is the predominant form in most cell types.
The activation of NF-κB p65 is mediated by phosphoryl-
ation at Ser529, Ser536 and Ser276 residues [42]. However,
the different functions of phosphorylation at these resi-
dues in arterial calcification have not been identified. In
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phorylation at Ser536 and Ser276, but not at Ser529,
abolishes NF-κB p65 activity. These findings provide
direct evidence that phosphorylation of NF-κB p65 at
Ser536 and Ser276 is required for β-GP-induced NF-κB
activation in the osteoblastic differentiation of human
CVSMCs.
Conclusion
In conclusion, GLP-1RA exenatide can inhibit osteo-
blastic differentiation and calcification of human CVSMCs
through the NF-κB/RANKL signaling pathway. This finding
may represent a new therapeutic potential in arterial calcifi-
cation for GLP-1RA, which is currently undergoing clinical
trials for the treatment of type 2 diabetes.
Abbreviations
β-GP: β-glycerol phosphate; ALP: Alkaline phosphatase; OC: Osteocalcin;
Runx2: Core binding factor α1; VSMCs: Vascular smooth muscle cells;
CVSMCs: Calcifying vascular smooth muscle cells; NF-κB: Nuclear Factor κB;
RANKL: Receptor activator of nuclear factor-κB ligand; GLP-1RA: Glucagon-like
peptide-1 receptor agonists; GLP-1R: Glucagon-like peptide-1 receptor;
CVSMCs: Calcifying vascular smooth muscle cells; SPSS: Statistical package for the
social science; siRNA: Small interference RNA; MAPK: Mitogen-activated protein
kinase; AMPK: AMP-activated protein kinase; JNK: c-Jun N-terminal kinase;
OPG: Osteoprotegerin; ERK: Extracellular signal-regulated kinase; RANK: Nuclear
factor κB receptor activator; NEAT: Nuclear factor of activated T-cells.
Competing interests
All authors declared that they have no competing interests.
Authors’ contributions
JKZ, PT, YJW, and YW carried out the molecular and cellular studies. JKZ and
PT participated in the drafted the manuscript. JYH, ZYT, and WH participated
in the graph preparation and the statistical analysis. YSL conceived of the
study, and participated in its design and coordination and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgments
This study was supported by the National Natural Science Foundation of
China (No.81370931), the National Basic Research Program of China (No.
2014CB910500), the Hunan Provincial Natural Science Foundation of China
(No. 13JJ3023), and Hunan Provincial Science and Technology Program
(No.2014FJ6065).
Received: 21 July 2014 Accepted: 29 October 2014
References
1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E,
Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S,
Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J: Diabetes
mellitus, fasting blood glucose concentration, and risk of vascular
disease: a collaborative meta-analysis of 102 prospective studies. Lancet
2010, 375:2215–2222.
2. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular
disease among adults with previously diagnosed diabetes. JAMA 2004,
291:335–342.
3. Lee YS, Jun HS: Anti-diabetic actions of glucagon-like peptide-1 on
pancreatic beta-cells. Metabolism 2014, 63:9–19.
4. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk
P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE:
Exenatide reduces infarct size and improves cardiac function in a
porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009,
53:501–510.5. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2
diabetes. Lancet 2006, 368:1696–1705.
6. Meloni AR, DeYoung MB, Han J, Best JH, Grimm M: Treatment of
patients with type 2 diabetes with exenatide once weekly versus oral
glucose-lowering medications or insulin glargine: achievement of
glycemic and cardiovascular goals. Cardiovasc Diabetol 2013, 12:48.
7. Paul SK, Maggs D, Klein K, Best JH: Dynamic risk factors associated with
non-severe hypoglycaemia in patients treated with insulin glargine or
exenatide once weekly. J Diabetes 2014, doi: 10.1111/1753-0407.12208.
8. Mafong DD, Henry RR: Exenatide as a treatment for diabetes and obesity:
implications for cardiovascular risk reduction. Curr Atheroscler Rep 2008,
10:55–60.
9. Brechow A, Slesaczeck T, Münch D, Nanning T, Paetzold H, Schwanebeck U,
Bornstein S, Weck M: Improving major amputation rates in the
multicomplex diabetic foot patient: focus on the severity of peripheral
arterial disease. Ther Adv Endocrinol Metab 2013, 4:83–94.
10. Liu YS, Lu Y, Liu W, Xie H, Luo XH, Wu XP, Yuan LQ: Liao EY:Connective
tissue growth factor is a down stream mediator for preptin-induced
proliferation and differentiation in human osteoblasts. Amino Acids 2010,
38:763–769.
11. Yuan LQ, Zhu JH, Wang HW, Liang QH, Xie H, Wu XP, Zhou H, Cui RR,
Sheng ZF, Zhou HD, Zhu X, Liu GY, Liu YS, Liao EY: RANKL is a downstream
mediator for insulin-induced osteoblastic differentiation of vascular
smooth muscle cells. PLoS One 2011, 6:e29037.
12. Massy ZA, Drüeke TB: Vascular calcification. Curr Opin Nephrol Hypertens
2013, 22:405–412.
13. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, Cozzolino M:
Combined effects of ascorbic acid and phosphate on rat VSMC
osteoblastic differentiation. Nephrol Dial Transplant 2012, 27:122–127.
14. Zhan JK, Wang YJ, Wang Y, Wang S, Tan P, Huang W, Liu YS: The
mammalian target of rapamycin signalling pathway is involved in
osteoblastic differentiation of vascular smooth muscle cells. Can J Cardiol
2014, 30:568–575.
15. Zhan JK, Wang YJ, Wang Y, Tang ZY, Tan P, Huang W, Liu YS:
Adiponectin attenuates the osteoblastic differentiation of vascular
smooth muscle cells through the AMPK/mTOR pathway. Exp Cell Res
2014, 323:352–358.
16. Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M, Haase
KK, Dempfle CE, Borggrefe M: Expression of bone sialoprotein and bone
morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004,
13:560–566.
17. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T,
Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition
associated with calcification upregulation of cbfα1 and downregulation
of smooth muscle lineage markers. Circ Res 2001, 89:1147–1154.
18. Liu H, Lu Q, Huang K: Selenium suppressed hydrogen peroxide-induced
vascular smooth muscle cells calcification through inhibiting oxidative
stress and ERK activation. J Cell Biochem 2010, 111:1556–1564.
19. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC: Novel aspects on RANK
ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif
Tissue Int 2004, 74:103–106.
20. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan
HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient
mice develop early onset osteoporosis and arterial calcification. Genes
Dev 1998, 12:1260–1268.
21. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G,
Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin
reverses osteoporosis by inhibiting endosteal osteoclasts and prevents
vascular calcification by blocking a process resembling
osteoclastogenesis. J Exp Med 2000, 192:463–474.
22. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B,
Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell
calcification through a RANK-BMP4-dependent pathway. Circ Res 2009,
104:1041–1048.
23. Aoki A, Murata M, Asano T, Ikoma A, Sasaki M, Saito T, Otani T, Jinbo S,
Ikeda N, Kawakami M, Ishikawa SE: Association of serum osteoprotegerin
with vascular calcification in patients with type 2 diabetes. Cardiovasc
Diabetol 2013, 12:11.
24. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM,
Bandinelli S, Zauli G: Association of tumor necrosis factor-related
Zhan et al. Cardiovascular Diabetology 2014, 13:153 Page 10 of 10
http://www.cardiab.com/content/13/1/153apoptosis-inducing ligand with total and cardiovascular mortality in
older adults. Atherosclerosis 2011, 215:452–458.
25. Shan PF, Lu Y, Cui RR, Jiang Y, Yuan LQ, Liao EY: Apelin attenuates the
osteoblastic differentiation of vascular smooth muscle cells. PLoS One
2011, 6:e17938.
26. Liao XB, Zhou XM, Li JM, Yang JF, Tan ZP, Hu ZW, Liu W, Lu Y, Yuan LQ:
Taurine inhibits osteoblastic differentiation of vascular smooth muscle
cells via the ERK pathway. Amino Acids 2008, 34:525–530.
27. Shi Y, Tohyama Y, Kadono T, He J, Miah SM, Hazama R, Tanaka C, Tohyama K,
Yamamura H: Protein-tyrosine kinase Sykis required for pathogen
engulfment in complement-mediated phagocytosis. Blood 2006,
107:4554–4562.
28. Callegari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M: Increased
Calcification in Osteoprotegerin-Deficient Smooth Muscle Cells:
Dependence on Receptor Activator of NF-κB Ligand and Interleukin 6.
J Vasc Res 2014, 51:118–131.
29. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD,
Bai XC: Metformin stimulates osteoprotegerin and reduces RANKL
expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011,
112:2902–2909.
30. Lee SK, Kalinowski J, Jastrzebski S, Lorenzo JA: 1,25(OH)2 vitamin
D3-stimulated osteoclast formation in spleen-osteoblast cocultures
is mediated in part by enhanced IL-1 alpha and receptor activator
of NF-kappa B ligand production in osteoblasts. J Immunol 2002,
169:2374–2380.
31. Kahn SE: The relative contributions of insulin resistance and beta-cell
dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia
2003, 46:3–19.
32. Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, Wu G, Shi L, Feng Z, Qiu L, Li Q, Guo X,
Luo Z, Lu J, Shan Z, Yang W, Ji Q, Yan L, Li H, Yu X, Li S, Zhou Z, Lv X, Liang Z,
Lin S, Zeng L, Yan J, Ji L, Weng J: Comparison of the effects on glycaemic
control and β-cell function in newly diagnosed type 2 diabetes patients
of treatment with exenatide, insulin or pioglitazone: a multicentre
randomized parallel-group trial (the CONFIDENCE study). J Intern Med 2014,
doi: 10.1111/joim.12293.
33. Bounthavong M, Tran JN, Golshan S, Piland NF, Morello CM, Blickensderfer
A, Best JH: Retrospective cohort study evaluating exenatide twice daily
and long-acting insulin analogs in a Veterans Health Administration
population with type 2 diabetes. Diabetes Metab 2014, 40:284–291.
34. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ: Effects of
exenatide vs metformin on endothelial function in obese patients with
pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64.
35. Vergès B, Bonnard C, Renard E: Beyond glucose lowering: glucagon-like
peptide-1 receptor agonists, body weight and the cardiovascular system.
Diabetes Metab 2011, 37:477–488.
36. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like
peptide 1 can directly protect the heart against ischemia/reperfusion
injury. Diabetes 2005, 54:146–151.
37. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y,
Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to
endothelial cells and attenuation of atherosclerotic lesion by a
glucagonlike peptide-1 receptor agonist, exendin-4. Diabetes 2010,
59:1030–1037.
38. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM,
Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM: Novel fusion of
GLP-1 with a domain antibody to serum albumin prolongs protection
against myocardial ischemia/reperfusion injury in the rat. Cardiovasc
Diabetol 2013, 12:148.
39. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV,
Boulton AJ, Alexander MY: The RANKL/RANK/OPG signaling pathway
mediates medial arterial calcification in diabetic Charcot neuroarthropathy.
Diabetes 2011, 60:2187–2196.
40. Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H,
Miyake T, Yoshizumi M, Rakugi H, Morishita R: Cross-talk of receptor activator
of nuclear factor-κB ligand signaling with renin-angiotensin system in
vascular calcification. Arterioscler Thromb Vasc Biol 2013, 33:1287–1296.41. Mazière C, Salle V, Gomila C, Mazière JC: Oxidized low density lipoprotein
enhanced RANKL expression in human osteoblast-like cells. Involvement
of ERK, NFkappaB and NFAT. Biochim Biophys Acta 2013, 1832:1756–1764.
42. Hochrainer K, Racchumia G, Anrather J: Hypo-phosphorylation leads to
nuclear retention of NF-κB p65 due to impaired IκBα gene synthesis.
FEBS Lett 2007, 581:5493–5499.
doi:10.1186/s12933-014-0153-4
Cite this article as: Zhan et al.: Exenatide can inhibit calcification of human
VSMCs through the NF-kappaB/RANKL signaling pathway. Cardiovascular
Diabetology 2014 13:153.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
